REAL PEOPLE.
REAL STORIES.
HAJARStudent, artist, and actual Oxbryta patient
HEAR FROM PEOPLE LIVING WITH SICKLE CELL
Living with sickle cell affects different people in different ways. Hear from real people as they share their unique stories and reflect on life with sickle cell and treatment with Oxbryta.
MEET HAJAR
Hajar and her mother and caregiver Mapillar reflect on how sickle cell has impacted Hajar’s life at home and school.
“I knew of the benefits of Oxbryta based on discussions with the doctor and doing my own research.”
— MAPILLAR
Mother, designer, and caregiver of an actual Oxbryta patient
MEET TULLY
Tully and her mother and caregiver Mapillar share the story of Tully’s sickle cell journey to less unpredictable days with Oxbryta.
“I went for my first appointment after starting my Oxbryta journey and realized that my hemoglobin rose.”
— TULLY
High school senior, trumpet player, and actual Oxbryta patient
MEET ABRAHAM
Abraham opens up about sickle cell, his treatment journey so far, and why it’s important that he finally shares his story.
“I’m hoping my story helps at least one person. Maybe it’ll inspire somebody.”
— ABRAHAM
Soccer fan, nurse, and actual Oxbryta patient
MEET ARELYS
Alongside her husband, Arelys describes how a wide support system and Oxbryta treatment has helped to manage her sickle cell.
“With sickle cell, you kind of have to plan your life around it, but since I’ve started taking Oxbryta, it has made a difference.”
— ARELYS
Mother, avid traveler, and actual Oxbryta patient
“The fact that Oxbryta is treating sickle cell…means everything.”
— MUYIWA
Father, bongo player, and actual Oxbryta patient
Talk to your healthcare provider to see if Oxbryta could be right for you.
FIND HELPFUL TIPS FOR CAREGIVERS
TIPS FOR CAREGIVERS
IMPORTANT SAFETY INFORMATION AND INDICATION
Do not take OXBRYTA if you or your child have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.
Before taking OXBRYTA, tell your healthcare provider about all of your medical conditions, including if you or your child:
- have liver problems
- are pregnant or plan to become pregnant. It is not known if OXBRYTA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if OXBRYTA can pass into your breastmilk and if it can harm your baby. Do not breastfeed during treatment with OXBRYTA and for at least 2 weeks after the last dose.
Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work and may affect the results of certain blood tests. Keep a list of all your medicines and show it to your healthcare provider.
What should I avoid while taking OXBRYTA?
Do not take St. John’s wort during treatment with OXBRYTA.
What are the possible side effects of OXBRYTA?
OXBRYTA can cause serious side effects, including:
Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:
- rash
- hives
- shortness of breath (difficult breathing)
- swelling of the face
The most common side effects of OXBRYTA include:
- headache
- diarrhea
- stomach-area (abdominal) pain
- nausea
- rash or hives
- fever
The most common side effects of OXBRYTA in children ages 4 to less than 12 years of age include:
- fever
- vomiting
- rash
- stomach-area (abdominal) pain
- diarrhea
- headache
These are not all the possible side effects of OXBRYTA.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).
Keep OXBRYTA and all medicines out of the reach of children.
INDICATION
What is OXBRYTA?
OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 4 years of age and older.
It is not known if OXBRYTA is safe and effective in children with sickle cell disease below 4 years of age.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Oxbryta®, GBT Source®, GBT Source Solutions® are registered trademarks of Global Blood Therapeutics, Inc., a wholly owned subsidiary of Pfizer Inc. All other trademarks are the property of their respective owners.
© 2023 Pfizer Inc. All Rights Reserved. P-VOX-US-00098 v9
This site is intended for residents of the United States, Puerto Rico, and US territories.
MORE Back to top
© 2023 Pfizer Inc. All Rights Reserved.